Amide Derivatives as Alpha-7 Nicotinic Receptor PAMs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nicotinic receptor modulators, particularly for the α7 subtype, face challenges such as non-specific effects and limited access to the central nervous system, leading to suboptimal benefits and adverse effects, necessitating the development of novel compounds that selectively modulate α7 neuronal nicotinic receptors to treat cognitive disorders and pain without the drawbacks of chronic agonist treatment.
Innovation Solution
The development of novel amide derivatives that act as positive allosteric modulators (PAMs) of α7 neuronal nicotinic receptors, enhancing endogenous cholinergic transmission without direct receptor activation, thereby improving treatment efficacy while reducing adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chronic agonist treatment is used to modulate α7 NNRs, then therapeutic benefits for cognitive disorders are achieved, but adverse effects and non-specific effects increase
Solution Approach 1:
The patent transitions from using agonists that directly activate receptors to using positive allosteric modulators that enhance endogenous ligand binding. This fundamental mechanism change alters the pharmacological parameters, providing selective modulation without the adverse effects of chronic agonist treatment while maintaining therapeutic benefits for cognitive disorders
Solution Approach 2:
The positive allosteric modulators act as intermediaries that enhance the effect of endogenous acetylcholine rather than directly activating the receptor. This indirect mechanism allows for more physiologically appropriate modulation, reducing non-specific effects and adverse events while maintaining therapeutic efficacy
2Reliability
If current nicotinic receptor modulators are used, then some therapeutic effect is achieved, but access to central nervous system is limited
Solution Approach 1:
The patent develops novel amide derivatives with optimized physicochemical properties including enhanced lipophilicity and molecular weight parameters that improve blood-brain barrier penetration. These parameter optimizations allow the PAMs to effectively reach central nervous system targets while maintaining selective α7 NNR modulation
3Adaptability or versatility
If non-selective modulators are used, then broad receptor coverage is achieved, but specificity for α7 NNR is reduced
Solution Approach 1:
The patent designs modulators with specific molecular features including particular amide derivative structures and substituent patterns that create local chemical properties optimized for α7 NNR binding. This local optimization of molecular characteristics enables selective interaction with α7 receptors while minimizing off-target effects at other nicotinic receptor subtypes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to novel amide derivatives that are PAMs of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.